Prostate cancer: MRI with a blood test to avoid biopsies.
Posted by giorgiobertin on March 30, 2024
MRI of the prostate, combined with a blood test, can help determine whether a prostate lesion is a clinically significant cancer.
A new meta-analysis conducted by researchers at Brigham and Women’s Hospitalsuggests that doctors and patients can avoid unnecessary prostate biopsies by combining MRI findings of the prostate with prostate-specific antigen (PSA) density.
“With this new analysis, we sought to see how MRI can help urologists decide which patients to biopsy and which patients may not need aggressive diagnosis and treatment.” says the professor. Philip H. Cook.
This new approach to diagnosing clinically significant prostate cancer may reduce patient harm and healthcare costs resulting from prostate biopsies. Their results were published in “JAMA Network Open“.
Read the full text of the article:
Magnetic Resonance Imaging, Clinical, and Biopsy Findings in Suspected Prostate Cancer: A Systematic Review and Meta-Analysis.
Haj-Mirzaian A, Burk KS, Lacson R, et al.
JAMA Netw Open. 2024;7(3):e244258. doi:10.1001/jamanetworkopen.2024.4258
Source: Brigham and Women’s Hospital
This entry was posted on marzo 30, 2024 a 6:16 am and is filed under News-research. Tagged: diagnostics, oncology, radiology, urology. You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a responseor trackback from your own site.